Artrya Limited (AU:AYA)
ASX:AYA
Want to see AU:AYA full AI Analyst Report?
AYA Stock Chart & Stats
AU$4.10
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$4.10
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.61 - AU$5.24
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$744.67M
Enterprise ValueAU$493.44M
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta2.21
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding159,799,500
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside48.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)AU$6.45M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetA low debt load provides durable financial flexibility for an early-stage medical tech firm. It reduces bankruptcy risk, supports continued R&D and commercialization spending, and makes future financing less pressured, helping sustain operations while scaling clinical validation.
Emerging Revenue TractionFirst reported revenue signals initial commercialisation and a move from pure R&D to product deployment. While currently small, durable significance lies in validating go-to-market execution and enabling a foundation for scaling sales and proving operating-leverage potential over the next 2–6 months.
Focused Cardiovascular AI ProductA narrow, clinically focused product targeting coronary angiography creates a clear use-case and integration pathway into cardiology workflows. Structural tailwinds for AI in medical imaging and the high switching costs of clinical validation create potential for a durable niche and sticky customer relationships.
Bears Say
Sustained Operating Cash BurnLarge, persistent negative operating and free cash flow indicates ongoing funding needs and reliance on external capital. Over months this can force dilutive equity raises or constrain commercialization investments, limiting ability to scale clinical validation and sales without new financing.
No Demonstrated Operating LeverageThe company has yet to show margin expansion as revenue grows; fixed-cost intensity and negligible revenue mean scaling may not translate to profitability without meaningful revenue gains. This structural uncertainty prolongs the path to sustainable margins and returns.
Declining Equity And Negative ROEOngoing losses have eroded shareholders' equity and produced negative ROE, signaling value destruction. Persistently negative returns limit internal funding capacity, weaken balance-sheet resilience, and increase the likelihood of dilutive capital raises or constrained strategic options.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.60 and its highest was AU$5.24 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$744.67M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 98 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.085.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 159,799,500 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.10 (48.78% Upside)
AU$6.10 (48.78% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-35.63%
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.10
▲(48.78% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―
Options Prices
Currently, No data available
---